An in vivo demonstration of the antianaphylactic effect of terbutaline

Publisher Website
Google Scholar
Abstract
Allergen-mediated histamine release was measured in small samples of blood in atopic patients before and following ingestion of 2 tablets of the .beta.-adrenergic bronchodilator terbutaline (5 mg) or placebo. No significant variation of histamine release was observed in the placebo group whereas a statistically significant decrease (maximally 45% of basal value) was found in 4 of the 5 patients receiving terbutaline. The mean reduction was about 25% of basal allergen-mediated histamine release. The inhibition was observed 1 h after taking the drug and persisted for at least 5 h. The amount of histamine released by antigen was again at its basal value 24 h later. Terbutaline, at what are considered therapeutic doses, has an antianaphylactic action which might be of interest in the treatment of atopic disorders.

This publication has 15 references indexed in Scilit: